- Home/In The News/Blog/503b Compounding
23
September2014
category:
503b CompoundingHospira Issues a Voluntary Nationwide Recall
Hospira initiated a voluntary nationwide user-level recall of one lot of Heparin Sodium, 1000 USP Heparin Units/500 mL (2 USP Heparin Units/mL), in 0.9% Sodium Chloride Injection, 500 mL, NDC 0409-7620-03 Lot 41-046-JT with an expiration date of 01NOV 2015. This action is due to one confirmed customer report of particulate in a single unit. […]
read more23
September2014
category:
503b CompoundingSun Pharmaceutical’s woes deepen as US arm Taro recalls Warfarin from markets
MUMBAI: Sun Pharma’s recall worries continue with its American subsidiary Taro recalling its leading blood clot drug from the market after the USFDA found that the product did not meet its quality norms. Taro has recalled Warfarin Sodium after the USFDA faulted its poor quality. This is the third such recall for Sun which agreed to buy troubled fellow drug maker Ranbaxy in […]
read more23
September2014
category:
503b CompoundingCanadians kept in dark about defective drugs
North American patients have been put at risk by prescription drugs that Canadian pharmaceutical companies sold with knowledge that their products were defective, a Star investigation has found. Using records obtained through U.S. freedom of information laws, the Star also found other Canadian companies have: Hidden, altered and in some cases destroyed test data that […]
read more